Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Adriamycin RDF (doxorubicin)
- mitomycin
Interactions between your drugs
DOXOrubicin mitoMYcin
Applies to: Adriamycin RDF (doxorubicin), mitomycin
MONITOR: Limited data suggest that mitomycin C and doxorubicin have synergistic cardiotoxicity. In one study of 91 patients who failed doxorubicin therapy and who were then given mitomycin C, 14 (15.3%) developed heart failure, compared with 3 of 89 (3.4%) in a control group of patients who received doxorubicin without mitomycin C.
MANAGEMENT: Until more data are available, careful monitoring of heart function (noninvasive testing with echocardiography and/or multigated blood pool scanning and ECG) is recommended when these drugs are given together or sequentially.
References (1)
- Buzdar AU, Legha SS, Tashima CK, et al. (1978) "Adriamycin and mitomycin C: possible synergistic cardiotoxicity." Cancer Treat Rep, 62, p. 1005-8
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
Antineoplastic antibiotics
Therapeutic duplication
The recommended maximum number of medicines in the 'antineoplastic antibiotics' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'antineoplastic antibiotics' category:
- Adriamycin RDF (doxorubicin)
- mitomycin
Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Carvykti
Carvykti (ciltacabtagene autoleucel) is a treatment for relapsed or refractory multiple myeloma ...
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Talvey
Talvey is used to treat relapsed or refractory multiple myeloma. Includes Talvey side effects ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.